BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

The Food and Drug Administration is reportedly expected to release detailed data about Pfizer's coronavirus vaccine on Tuesday as regulators consider whether to clear it for emergency use. The data will give the public an in-depth look at how well the vaccine works before the FDA's vaccine committee meets Thursday to consider Pfizer's application for.

FDA to release detailed data on Pfizer's COVID-19 vaccine

Biogen

CRISPR Therapeutics

Editas Medicine

Eli Lilly

Novo Nordisk

Roche Holding AG

Sanofi

One metric shows that decades of dominance treating diabetes has created unrivaled profitability.

How You Can Profit From the Best-Managed Drugmaker on Earth

The U.K. will receive just 4 million doses of the vaccine being developed by AstraZeneca and the University of Oxford — by year-end — short of the 30 million doses hoped for.

World watches as first person receives Pfizer-BioNTech COVID shot

Moderna

Novavax

The companies with the biggest gains won't necessarily be those with the highest sales of coronavirus vaccines.

$40 Billion COVID Vaccine Market in 2021: These 3 Stocks Are Likely to Be the Biggest Winners

The UK is the first country to approve Pfizer's vaccine and is beginning its rollout on Tuesday.

COVID-19 vaccine: 90-year-old woman becomes first to receive Pfizer vaccine in UK

Pfizer Inc (NYSE: PFE) has told the outgoing Donald Trump administration that it cannot supply a considerable amount of additional doses of its COVID-19 vaccine to the United States until late June because other countries have hastened to secure the supply, the Washington Post reported Monday. What Happened: The development means that the U.S. government may have difficulty in procurement beyond the 100 million doses it has already secured earlier this year, according to the Post.

Pfizer Tells US It Can't Provide Substantial Extra Doses Before June As Other Countries Have Already Secured Supply: WaPo

A member of a United States Food and Drug Administration committee on vaccines said that the agency could issue an emergency authorization for Pfizer Inc's (NYSE: PFE) COVID-19 vaccine as early as Friday. What Happened: James Hildreth, a member of the Vaccines and Related Biological Products Advisory Committee, said on NBC's “Weekend Today” show that the body would meet on Thursday to review the COVID-19 vaccine developed by Pfizer and its German partner BioNTech SE (NASDAQ: BNTX).

Pfizer COVID-19 Vaccine Could Get Emergency Approval By Friday, FDA Advisor Says

Bahrain joins U.K. in authorizing emergency use of Pfizer–BioNTech vaccine

Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) is first among coronavirus vaccine developers to secure authorization for emergency use of candidate BNT162b2, with the first approval granted by U.K. regulators. Scale-Down Previously Disclosed: An analyst at BofA Securities shrugged off a Thursday report in The Wall Street Journal that hinted at manufacturing constraints, resulting in a modest pullback in Pfizer shares.

Pfizer's Scaled-Down COVID-19 Vaccine Manufacturing Plan Is Old News: BofA

The German biotech and its partner Pfizer announced great news about their coronavirus vaccine candidate last month, and kicked off December with a big win.

Why BioNTech Stock Soared 46% in November

Pfizer's Covid-19 vaccine has been approved for emergency use in the United Kingdom, with initial shots likely to be given as soon as next week. The U.K is the first western country to ratify the shot and the country is expected to be allotted between four million to five million doses of the.

What The Approval Of The Covid Vaccine In The U.K Means For Pfizer Stock

At the 2020 Forbes Healthcare Summit, Albert Bourla is already looking beyond his company's vaccine success and into a post-pandemic world.

Pfizer CEO Is ‘Confident' In Covid-19 Vaccine Rollout And Looking Beyond The Pandemic

Pfizer had been submitting data on its vaccine on a "rolling basis" to the U.K., meaning regulators there were able to review the data in real-time.

Why Pfizer's Covid vaccine has been authorized in the U.K. but not the U.S. yet

BioNTech (BNTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

BioNTech (BNTX) Surges: Stock Moves 6.2% Higher

APA Corporation

Chevron

Devon Energy

Diamondback Energy

TechnipFMC

Occidental Petroleum

The top five gainers of the S&P 500 in November were all energy firms - Occidental Petroleum (OXY), Devon Energy (DVN), Apache (APA), Diamondback Energy (FANG) and TechnipFMC (FTI).

Oil Ends Higher on Vaccine News Despite EIA's Bearish Report

European Union officials slammed the UK on Wednesday for rushing its landmark approval of Pfizer's coronavirus vaccine, saying health authorities shouldn't put speed ahead of safety. The British government cleared the COVID-19 shot early Wednesday, just 10 days after it started examining data from large-scale clinical trials run by Pfizer and its German partner, BioNTech.

European officials say UK rushed approval of Pfizer COVID-19 vaccine

The healthcare leaders became the first to receive emergency authorization for their coronavirus vaccine.

Why Pfizer and BioNTech Stocks Popped Today

The U.K. government granted emergency use authorization to the COVID-19 vaccine being developed by Pfizer Inc. and German partner BioNTech SE with some fanfare on Wednesday, but experts cautioned that the news does not mean the pandemic is close to being over.

What we still don't know about COVID vaccines after the U.K.'s emergency-use authorization of the Pfizer-BioNTech candidate

Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) earned the distinction of being the first companies to receive regulatory authorization for emergency use of their investigational coronavirus vaccine candidate BNT162b2 following a positive verdict from the United Kingdom's drug regulator. Here's what investors should know about the combo's vaccine candidate:

What Pfizer, BioNTech Investors Need To Know About COVID-19 Vaccine With Conditional UK Approval

Merck

COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.

COVID-19 Vaccines Are on the Way and Major Players Are Cashing In

The vaccine will begin to be available to the public next week, says the government.

Pfizer and BioNTech's Coronavirus Vaccine Approved for Use in the U.K.

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.

Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.

Encouraging News on COVID-19 Vaccine

Vaccine hopes are starting to be fulfilled as the first COVID-19 vaccine gets authorized.

Pfizer/BioNTech COVID-19 Vaccine Approved in the U.K.

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

News for BioNTech SE Stock (BNTX)